EUCTR2008-007246-60-DK进行中（未招募）1 期
enalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma - LENA-BERIT
ordic Lymphoma Group0 个研究点目标入组 60 人开始时间: 2010年3月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age >65 years, or age = 65 years unable to tolerate high dose chemotherapy with autologous stem cell support
- •2. Histologically confirmed (according to the WHO classification) mantle cell lymphoma, stage II-IV, in need of treatment due to at least one of the following symptoms:
- •a. Bulky disease: nodal or extranodal mass > 7cm in its greater diameter
- •b. B symptoms
- •c. Elevated serum LDH
- •d. involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)
- •e. symptomatic nodal or splenic enlargement
- •f. compressive syndrome
- •g. pleural/peritoneal effusion
- •h. anemia (<12), thrombocytopenia (< 100) or neutropenia (<1.5) caused by bone marrow infiltration of lymphoma
- •3. No previous treatment for lymphoma except radiotherapy or one cycle of any chemotherapy regimen for lymphoma.
- •4. WHO performance status 0 – 3
- •5. Written informed consent.
- •6. Female subjects of childbearing potential† must:
- •a. Understand that the study medication is expected to have a teratogenic risk
- •b. Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhoea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis. The following are effective methods of contraception*
- •i. Implant**
- •ii. Levonorgestrel-releasing intrauterine system (IUS)**
- •iii. Medroxyprogesterone acetate depot
- •iv. Tubal sterilisation
- •v. Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses
- •vi. Ovulation inhibitory progesterone-only pills (i.e., desogestrel)
- •* Combined oral contraceptive pills are not recommended. If a subject was using combined oral contraception, she must switch to one of the methods above. The increased risk of VTE continues for 4 to 6 weeks after stopping combined oral contraception.
- •**prophylactic antibiotics should be considered at the time of insertion particularly in patients with neutropenia due to risk of infection
- •Copper-releasing intrauterine devices are generally not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with neutropenia or thrombocytopenia.
- •a. Understand that even if she has amenorrhea, she must follow all the advice on effective contraception.
- •b. She understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy.
- •c. Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. The test should ensure the subject is not pregnant when she starts treatment.
- •d. Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. These pregnancy tests should be performed on the day of the study visit or in the 3 days prior to the study visit. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
- •7. Male subjects must
- •a. Agree to use condoms throughout study drug the
排除标准
- •1. Impaired liver function (serum total bilirubin >34 mmol/L, except in case of haemolytic anemia or caused by lymphoma).
- •2. Absolute neutrophil count (ANC) <1.0x 109, unless caused by bone marrow infiltration by lymphoma.
- •3. Platelet count <60 x 109, unless caused by bone marrow infiltration by lymphoma.
- •4. Creatinine clearance below 50 ml/min (Cockcroft-Gault)
- •5. Known HIV positivity.
- •6. Known seropositivity for HCV, HBsAg, anti-HBc, or other active infection uncontrolled by treatment.
- •7. Psychiatric illness or condition which could interfere with the subjects’ ability to understand the requirements of the study.
- •8. Requirement of corticosteroid therapy at a dose >10 mg prednisolone/day.
- •9. Pregnant or lactating females.
研究者
相似试验
进行中（未招募）
1 期
enalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma - LENA-BERITMedDRA version: 14.1Level: PTClassification code 10026805Term: Mantle cell lymphoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10026804Term: Mantle cell lymphoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10026803Term: Mantle cell lymphoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Mantle cell lymphomaEUCTR2008-007246-60-SEordic Lymphoma Group50
进行中（未招募）
1 期
enalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma - LENA-BERITMantle cell lymphomaEUCTR2008-007246-60-FIordic Lymphoma Group60
已完成
1 期
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.Mantle Cell LymphomaNCT00963534Lund University Hospital51
进行中（未招募）
1 期
enalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance – A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples MyelomMedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2008-000007-28-DEniversitaetsklinikum Wuerzburg190
进行中（未招募）
1 期
BENDAMUSTINE, LENALIDOMIDE AND RITUXIMAB (R2-B)COMBINATION AS A SECOND-LINE THERAPY FOR FIRST RELAPSED-REFRACTORY MANTLE CELL LYMPHOMAS: A PHASE II STUDYPatients with first relapsed/refractory mantle cell lymphoma (MCL)MedDRA version: 14.1Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-005461-21-ITFONDAZIONE ITALIANA LINFOMI ONLUS42